According to statistics, approximately 429,800 newly diagnosed cases of bladder cancer occurred and caused 165,100 deaths in 2012 worldwide[@b1]. For prostate cancer, about 1.1 million new cases accounts for the second frequently diagnosed cancer[@b1]. Besides, renal cell carcinoma is the seventh most common cancer and arises about 209,000 new cases and 102,000 deaths per year[@b2]. Urinary tract cancers have a serious harm to human health[@b3]. Smoking is the most well-known risk factor for bladder cancer and renal cell carcinoma, which could increase the risk to be more than 2-fold compared with nonsmokers. There are other environmental risk factors which have been reported to increase risk of urinary tract cancers, such as occupational exposure and obesity[@b1][@b4]. Epidemiology studies have indicated that except for environmental risk factors, genetic susceptibility and their interaction with environmental factors play a key role in the pathogenesis of cancers[@b5][@b6][@b7].

Genome-wide association study (GWAS) and its corresponding meta-analysis have successfully identified several risk loci and regions, which had small or moderate effect to increase the risk of diseases[@b8][@b9][@b10]. Presently, multiple urinary tract cancers risk--associated SNPs are mostly common and locate in non-coding regions of the genome[@b11][@b12][@b13][@b14]. However, these risk-associated SNPs contribute little or moderate effect to heritability of urinary tract cancers. The Common Disease-Rare Variant Hypothesis suggests that the additional heritability can be explained by low frequency and rare variants with stronger effect[@b8][@b15][@b16].

In recent, an imputation-based genome wide association study had identified two rare variants rs11571833 (c.9976A \> T) in *BRCA2* (OR = 2.47, *P* = 4.74 × 10^−20^) and rs17879961 (c.470T \> C) in *CHEK2* (OR = 0.38, *P* = 1.27 × 10^−13^), which have large effect on lung cancer in populations of European ancestry[@b17]. *BRCA2* and *CHEK2*, two important DNA repaired genes, acted a crucial role in response to DNA alterations and involved in maintenance of genome stability[@b18][@b19][@b20]. Long-term exposure of smoking may result in DNA accumulates damage, which can trigger cell-cycle deregulation and oncogenesis[@b21][@b22]. Germline rare variation of *BRCA2* and *CHEK2* that changes amino acid may alter their function of DNA damage repair, which may influence the risk of diseases[@b23]. Previous studies have shown that *BRCA2* and *CHEK2* confer susceptibility to multi-organ cancers, such as breast, lung, prostate and bladder cancer[@b24][@b25][@b26][@b27][@b28][@b29]. Furthermore, mounting evidence shows chemical carcinogens and reactive oxygen can induce damage to DNA in urothelial cells and polymorphisms in DNA repair genes might modify urothelial carcinoma risk[@b30]. In addition, the exposure of carcinogens was thought to be similar throughout the urinary tract and the urinary tract cancers are often multifocal[@b31]. We performed imputation analysis from dbGaP database to explore the association between rs11571833 and rs17879961 polymorphism and the risk of urinary tract cancers in the populations of European descent.

Results
=======

The characteristics of GWAS studies for urinary tract cancers
-------------------------------------------------------------

A total of three GWAS studies including 6,064 cases and 8,661 controls were enrolled in our study. The detailed characteristics of GWAS studies are shown in [Table 1](#t1){ref-type="table"}. In addition, the principal component analysis (PCA) showed there were no abnormal outlier samples in the study population ([Supplementary Fig. 1](#S1){ref-type="supplementary-material"}).

Association analysis for individual GWAS data and joint (pooled) GWAS data
--------------------------------------------------------------------------

Our logistic regression results are applied in [Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}. The imputation info of the two rare variants was mostly more than 0.9, which indicated the accuracy of our imputation result was high. The rs11571833\[T\] showed significant association with bladder cancer in Illumina 610 array (OR = 1.87, 95%CI = 1.21--2.87, *P* = 4.5 × 10^−3^). Simultaneously, rs17879961\[C\] was related with decreased the risk of renal cell carcinoma in Illumina 610 array and bladder cancer in Illumina 610 array (OR = 0.50, 95%CI = 0.33--0.77, *P* = 1.5 × 10^−3^ and OR = 0.71, 95%CI = 0.52--0.98, *P* = 0.036, separately).

In consideration of the relative small sample, we attempted to combine the original GWAS data to implement joint analyses. We merged genotype data across each cancer (three for bladder cancer and three for renal cell carcinoma) to increase the sample size. Totally, the sample size is 3591 cases and 4132 controls for bladder cancer, 1322 cases and 3428 controls for renal cell carcinoma, 1151 cases and 1101 controls for prostate cancer. Our results indicated that rs11571833\[T\] was significantly associated with increased the risk of bladder cancer (OR~combined~ = 1.70, 95%CI = 1.19--2.42 and *P*~combined~ = 3.6 × 10^−3^), but showed non-significant association between renal cell carcinoma and prostate cancer ([Table 2](#t2){ref-type="table"}). rs17879961\[C\] had a correlation with renal cell carcinoma (OR~combined~ = 0.63, 95%CI = 0.44--0.89 and *P*~combined~ = 1.0 × 10^−2^). There were no remarkable associations between rs17879961 and the other two cancers ([Table 3](#t3){ref-type="table"}). For the total three cancers, the results revealed that rs11571833\[T\] could increase 47% risk of urinary tract cancers (OR~combined~ = 1.47, 95%CI = 1.12--1.94 and *P*~combined~ = 5.7 × 10^−3^) and rs17879961\[C\] was associated with a significantly lower risk of urinary tract cancers (OR~combined~ = 0.73, 95%CI = 0.59--0.90 and *P*~combined~ = 3.7 × 10^−3^). In conclusion, rs11571833 may play a risk factor in urinary tract cancers predisposition, especially be associated with the risk of bladder cancer. Meanwhile, rs17879961 is associated with decreased risk of urinary tract cancers and mostly associated with the risk of renal cell carcinoma.

Meta-analysis across multiple GWAS databases
--------------------------------------------

Except for joint analysis, we also applied meta-analysis to assess the association between the two rare variants and urinary tract cancers. For rs11571833, we performed a meta-analysis from seven imputation association results and found that the association between rs11571833\[T\] and the risk of urinary tract cancers was significant (OR~meta~ = 1.45, 95%CI = 1.08--1.94 and *P*~meta~ = 0.013). In addition, a significant association between rs11571833\[T\] and bladder cancer was observed in the subgroup meta-analysis (OR~meta~ = 1.60, 95%CI = 1.12--2.29 and *P*~meta~ = 0.010; [Table 4](#t4){ref-type="table"} and [Fig. 1a](#f1){ref-type="fig"}). The result showed that rs17879961\[C\] was associated with decreased the risk of urinary tract cancers (OR~meta~ = 0.67, 95%CI = 0.53--0.85 and *P*~meta~ = 1.0 × 10^−3^) and had a protective effect on renal cell carcinoma (OR~meta~ = 0.51, 95%CI = 0.34--0.78 and *P*~meta~ = 2.0 × 10^−3^; [Table 5](#t5){ref-type="table"} and [Fig. 1b](#f1){ref-type="fig"}) by fixed effect model.

Discussion
==========

Genome stability is critical for preventing tumorigenesis. DNA damages can result in the activation of oncogenes and inactivation of tumor suppressor genes. DNA damage repaired systems involve in maintenance of genome stability and supply a crucial defense function against DNA-damaging agent, such as exposure of cigarette smoking and ultraviolet component of ionizing radiation, sunlight and genotoxic substance[@b22][@b32]. The main DNA damage repaired pathways include nucleotide-excision repair (NER), base-excision repair (BER), homologous recombination and end joining[@b33]. Previous studies have highlighted that inherited defects in the DNA repaired pathways may predispose to malignancy[@b22].

Recently, an imputation study identified two rare variants rs11571833 in *BRCA2* and rs17879961 in *CHEK2* were associated with lung cancer. *CHEK2* (checkpoint kinase 2 checkpoint homologue) plays an important role in encoding a pluripotent kinase which can induce cell cycle arrest or apoptosis in response to unrepaired DNA damage[@b34][@b35]. The missense variant rs17879961 (p.Ile157Thr) changes Isoleucine to Threonine at position 157 of the protein and it locates in a region coding for a functionally important FHA domain of *CHEK2* and injures binding of principal substrates. The rs17879961 (*CHEK2* p.Ile157Thr) substitution may alter its ability to bind p53, BRCA1 and Cdc25A proteins[@b4][@b36][@b37]. *BRCA2* (breast cancer early onset 2) is a widely known anti-oncogene and associated with the risk of breast cancer and ovarian cancer[@b38]. *BRCA2* also involves in the maintenance of genome stability through interacting with RAD51 recombinase, specifically in the homologous recombination pathway for DNA repair[@b39][@b40][@b41]. The variant rs11571833 (p.Lys3326X) leads to a stop codon, which results in loss of the final 93 amino acids of the BRCA2 protein. The interaction of RAD51 and BRCA2 plays a crucial role in BRCA2-mediated double strand-break repair. The C-terminus of BRCA2 contains a RAD51 binding domain and small protein sequence incorporating p.Lys3326X (amino acids 3265--3330) is capable of binding RAD51. Besides, an important serine involved in BRCA2-mediated repair process is close to this truncating mutation[@b41][@b42][@b43]. Above evidence invites that the SNP rs11571833 is functional in DNA damage repair pathway thus alter the genetic susceptibility of cancers. Previous studies have found that rs11571833 was associated with the risk of upper aerodigestive tract cancer (OR = 2.53)[@b21]. Besides, some studies suggest that rs11571833 have an association with risk of breast cancer[@b42]. Meanwhile, rs17879961 have been reported to be associated with a significantly lower incidence of lung or upper aerodigestive tract cancer, but increased the risk of thyroid cancer[@b34][@b44][@b45]. However, the effect of these two rare variants on urinary tract cancers remains largely unexplored.

In this study, we investigated the associations between rare genetic variants of rs11571833 and rs17879961 and the risk of urinary tract cancers (including bladder cancer, prostate cancer and renal cell carcinoma) and found that the rare variant rs11571833 (c.9976A \> T) was associated with increased risk of urinary tract cancers, especially associated with bladder cancer. Concurrently, rs17879961 (c.470T \> C) played a protective role in the urinary tract cancers carcinogenesis and mostly decreased the risk of renal cell carcinoma. Our meta-analyses result show highly consistency with joint analyses, which strengthen our conclusion that the rs11571833 is associated with increased the risk of urinary tract cancers and rs17879961 reduces urinary tract cancers predisposition. Interestingly, association signals of these two variants in urinary tract cancers (rs11571833, OR = 1.47 ; rs17879961, OR = 0.73) are in the same direction to lung cancer (rs11571833, OR = 2.47; rs17879961, OR = 0.38). It is noteworthy that the rare variants rs17879961 may impair function of CHEK2, but it was associated with decreased the risk of renal cell cancer. A speculation for the possible protective mechanism is that CHEK2 can have two opposite effects on damaged stem cells and it impedes stem cell division until DNA damage has been repaired or actives apoptosis if unrepaired DNA damage happened. Accumulating evidence has shown that in the circumstance of continued DNA damage by long-term exposure of tobacco, the normal stem cell defenses that involve CHEK2 can be attenuated by reducing the CHEK2 activity as a result of rs17879961 (p.Ile157Thr)[@b17][@b32][@b34].

There are several limitations in our study. Firstly, the available GWAS data published in dbGaP database provides relatively little samples, which may influence the power to identify the association between the rare variants and diseases. Furthermore, our analysis based on public database is short of relevant demography information applied in stratification analysis. Additionally, our study is an imputation-based analysis from public database and the ORs of two rare variants are relatively modest. Besides, the sample sizes of controls are unevenly matched with cases in some cohorts, which may result in sample bias. Further large well-designed studies in other independent populations and functional studies are needed to validate our findings. Meanwhile, the interaction between environmental exposures and genetic susceptibility should be also considered in the future research[@b32].

In conclusion, our imputation analysis results indicated that the rare variant rs11571833 (c.9976A \> T) showed an effect on urinary tract cancers predisposition, especially associated with increased the risk of bladder cancer. However, rs17879961 (c.470T \> C) may play a protective role in the urinary tract cancers carcinogenesis and notably decrease the risk of renal cell carcinoma. Association signals of these two variants in urinary tract cancers are in the same direction to lung cancer. These results suggest that *BRCA2* and *CHEK2* play an important role in the genetic susceptibility to urinary tract cancers.

Materials and Methods
=====================

Study population
----------------

GWAS data from three cancer studies were available, which were requested from dbGaP. Two genotype datasets were excluded because of low-density genotype panel and low sample size (These two datasets are genotyped by Illumina 240 array and Illumina 317 array separately, and their genome build are both build 35). In the final analysis, we included three bladder cancer studies, three renal cell carcinoma studies and one prostate cancer study, totally including 6,064 cases and 8,661 controls.

Quality control
---------------

First, we applied the LiftOver tool to convert study data from earlier genome builds (NCBI build 36) to NCBI build 37. Few SNPs that failed in the LiftOver were excluded from the imputation. Before performing imputation, we filtered the data to remove low-quality variants and individuals to increase the accuracy of the results. For individuals, (1) we excluded those missing rate per person \>5%; (2) excluded samples with ambiguous gender; (3) additional duplicates or probable relatives were excluded according to PI_HAT \> 0.5; SNPs filter criterion : (1) completion rate per locus \<95%; (2) minor allele frequency \<0.05; (3) Hardy-Weinberg Proportion for autosomal SNPs in control population with *P* \< 1.0 × 10^−6^; (4) A/T or C/G SNPs with MAF \>0.45.

Imputation analyses
-------------------

We used SHAPEIT, a highly accurate phasing algorithm, to infer the haplotypes underlying genotype data[@b46], then inputting into estimated GWAS haplotypes with IMPUTE2 for imputation. Imputation was conducted separately for each scan by IMPUTE2 Version 2.3.1 and using the 1000 Genomes Project data (version 3, March 2012 release) as reference dataset[@b47]. We executed imputation across a 5Mb genomic region that included rs11571833 and rs17879961 (chr13: 30472626--35472626 and chr22: 26621087--31621087 respectively). Test of association was performed by SNPTEST Version 2.5 software[@b48].

Statistical analyses
--------------------

An unconditional logistic regression model was applied to calculate the odds ratio (OR) and 95% confidence interval (CI) for each SNP in an additive model using SNPTEST software. We adjusted for some covariates such as age, gender, study and significant principle components (PCs). The principal component analysis (PCA) was carried out to assess for population stratification of study cohorts. Meta-analysis was conducted by Stata v.10 (Stata College, Taxas, US). Heterogeneity was evaluated by Cochran'Q and *I*^2^ statistics. *I*^2^ values ≥ 75% were considered to be significant heterogeneity. All statistical analyses were two-sided, and a *P* value \< 0.05 was considered statistically significant.
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###### Description of GWASs for urinary tract cancers.

  Tumor types                          Cases   Controls  Platform                        Published GWAS
  ----------------------------------- ------- ---------- ------------------------------ ----------------
  Bladder cancer                       1106      1048    Illumina Human1Mv1_C            Rothman[@b49]
  (phs000346.v1.p1)                     38       825     Illumina HumanHap550v3.0               
                                       2447      2259    Illumina Human610_Quadv1_B             
  Renal cell carcinoma                   9       845     Illumina HumanHap550v1.1         Purdue[@b13]
  (phs000351.v1.p1)                     672      2575    Illumina Human610_Quadv1_B             
                                        641       8      Illumina Human660W-Quad_v1_A           
  Prostate cancer (phs000207.v1.p1)    1151      1101    Illumina HumanHAP300V1.1         Yeager[@b50]

###### Logistic regression analysis of rs11571833 (c.9976A \> T) in BRCA2 and three urinary tract cancers in individual GWAS data.

  Study                            Info[a](#t2-fn1){ref-type="fn"}   Case/control   Maf[b](#t2-fn2){ref-type="fn"} case/control   OR[c](#t2-fn3){ref-type="fn"} (95%CI)   *P* value[c](#t2-fn3){ref-type="fn"}
  ------------------------------- --------------------------------- -------------- --------------------------------------------- --------------------------------------- --------------------------------------
  Bladder cancer_1M                             0.929                 1106/1048                    0.0087/0.0082                            1.06 (0.55--2.06)                            0.860
  Bladder cancer_550                            0.888                   38/825                     0.0132/0.0054                           4.10 (0.18--91.17)                            0.373
  Bladder cancer_610                            0.896                 2447/2259                    0.0127/0.0072                            1.87 (1.21--2.87)                           4.5E-03
  Bladder caner_combined                        0.872                 3591/4132                    0.0114/0.0073                            1.70 (1.19--2.42)                           3.6E-03
  Renal cell carcinoma_550                      0.899                   9/845                      0.0002/0.0060                           0.36 (0.00--178.19)                           0.746
  Renal cell carcinoma_610                      0.882                  672/2575                    0.0107/0.0072                            1.68 (0.81--3.49)                            0.166
  Renal cell carcinoma_660                      0.820                   641/8                      0.0098/0.0000                           2.82 (0.02--443.54)                           0.688
  Renal cell carcinoma_combined                 0.865                 1322/3428                    0.0097/0.0068                            1.60 (0.91--2.82)                            0.103
  Prostate cancer                               0.875                 1151/1101                    0.0071/0.0082                            0.85 (0.41--1.74)                            0.647
  Three cancers_combined                        0.874                 6064/8661                    0.0099/0.0071                            1.47 (1.12--1.94)                           5.7E-03

^a^Info: A measure of the observed statistical information for the estimate of allele frequency of the SNP using all individuals in the sample that are used for the test at each SNP. This measure has a maximum value of 1 that indicates that perfect information.

^b^Maf: minor allele frequency.

^c^OR, odds ration; CI, confidence interval. *P* was for addictive model.

###### Logistic regression of rs17879961 (c.470T \> C) in CHEK2 and three urinary tract cancers in individual GWAS data.

  Study                            Info[a](#t3-fn1){ref-type="fn"}   Case/control   Maf[b](#t3-fn2){ref-type="fn"} case/control   OR[c](#t3-fn3){ref-type="fn"} (95%CI)   *P* value[c](#t3-fn3){ref-type="fn"}
  ------------------------------- --------------------------------- -------------- --------------------------------------------- --------------------------------------- --------------------------------------
  Bladder cancer_1M                             0.297                 1106/1048                    0.0002/0.0000                      NA[d](#t3-fn4){ref-type="fn"}                        NA
  Bladder cancer_550                            0.930                   38/825                     0.0000/0.0061                            0.35 (0.02--7.11)                            0.491
  Bladder cancer_610                            0.973                 2447/2259                    0.0141/0.0196                            0.71 (0.52--0.98)                            0.036
  Bladder caner_combined                        0.966                 3591/4132                    0.0096/0.0118                            0.81 (0.60--1.10)                            0.183
  Renal cell carcinoma_550                      0.917                   9/845                      0.0000/0.0072                           0.36 (0.00--91.29)                            0.717
  Renal cell carcinoma_610                      0.975                  672/2575                    0.0099/0.0237                            0.50 (0.33--0.77)                           1.5E-03
  Renal cell carcinoma_660                      0.955                   641/8                      0.0170/0.0000                           2.85 (0.06--137.50)                           0.596
  Renal cell carcinoma_combined                 0.912                 1322/3428                    0.0125/0.0199                            0.63 (0.44--0.89)                            0.010
  Prostate cancer                               0.972                 1151/1101                    0.0076/0.0067                            1.14 (0.56--2.30)                            0.720
  Three cancers_combined                        0.971                 6064/8661                    0.0104/0.0142                            0.73 (0.59--0.90)                           3.7E-03

^a^Info: A measure of the observed statistical information for the estimate of allele frequency of the SNP using all individuals in the sample that are used for the test at each SNP. This measure has a maximum value of 1 that indicates that perfect information.

^b^Maf: minor allele frequency.

^c^OR, odds ration; CI, confidence interval. *P* was for addictive model.

^d^NA, not available.

###### Meta-analysis of rs11571833 (c.9976A \> T) in BRCA2 and three urinary tract cancers in individual GWAS data.

  Study                                                OR (95%CI)[a](#t4-fn1){ref-type="fn"}       *P* value   *P*~het~[c](#t4-fn3){ref-type="fn"}
  ------------------------------------------------ ---------------------------------------------- ----------- -------------------------------------
  Bladder cancer_1M                                              1.06 (0.55--2.06)                   0.860                       
  Bladder cancer_550                                             4.10 (0.18--91.17)                  0.373                       
  Bladder cancer_610                                             1.87 (1.21--2.87)                  4.5E-03                      
  Meta-analysis of three bladder cancers studies    1.60 (1.12--2.29)[b](#t4-fn2){ref-type="fn"}     0.010                    0.314
  Renal cancer_550                                              0.36 (0.00--178.19)                  0.746                       
  Renal cancer_610                                               1.68 (0.81--3.49)                   0.166                       
  Renal cancer_660                                              2.81 (0.02--443.54)                  0.688                       
  Meta-analysis of three renal cancers studies      1.66 (0.81--3.41)[b](#t4-fn2){ref-type="fn"}     0.167                    0.871
  Prostate cancer                                                0.85 (0.41--1.74)                   0.647                       
  Meta-analysis of all studies                      1.45 (1.08--1.94)[b](#t4-fn2){ref-type="fn"}     0.013                    0.521

^a^OR, odds ration; CI, confidence interval. *P* was for addictive model.

^b^OR and 95%CI were estimated from a fixed-effects model.

^c^*P* value of Cochran's Q-test for the heterogeneity.

###### Meta-analysis of rs17879961 (c.470T \> C) in CHEK2 and three urinary tract cancers in individual GWAS data.

  Study                                                OR (95%CI)[a](#t5-fn1){ref-type="fn"}       *P* value   *P*~het~[c](#t5-fn3){ref-type="fn"}
  ------------------------------------------------ ---------------------------------------------- ----------- -------------------------------------
  Bladder cancer_1M                                        NA[d](#t5-fn4){ref-type="fn"}              NA                         
  Bladder cancer_550                                             0.35 (0.02--7.11)                   0.491                       
  Bladder cancer_610                                             0.71 (0.52--0.98)                   0.036                       
  Meta-analysis of three bladder cancers studies    0.71 (0.51--0.97)[b](#t5-fn2){ref-type="fn"}     0.031                    0.642
  Renal cancer_550                                               0.36 (0.00--91.29)                  0.717                       
  Renal cancer_610                                               0.50 (0.33--0.77)                  1.5E-03                      
  Renal cancer_660                                              2.85 (0.06--137.50)                  0.596                       
  Meta-analysis of three renal cancers studies      0.51 (0.34--0.78)[b](#t5-fn2){ref-type="fn"}    2.0E-03                   0.678
  Prostate cancer                                                1.14 (0.56--2.30)                   0.720                       
  Meta-analysis of all studies                      0.67 (0.53--0.85)[b](#t5-fn2){ref-type="fn"}    1.0E-03                   0.438

^a^OR, odds ration; CI, confidence interval. *P* was for addictive model.

^b^OR and 95%CI were estimated from a fixed-effects model.

^c^*P* value of Cochran's Q-test for the heterogeneity.

^d^NA, not available.
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